Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
| Descriptor ID |
D042461
|
| MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 4 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 3 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 4 | 8 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights. Int J Mol Sci. 2026 Jan 26; 27(3).
-
Retinal Ischemia: Therapeutic Effects and Mechanisms of Paeoniflorin. Int J Mol Sci. 2025 Nov 11; 26(22).
-
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study. Graefes Arch Clin Exp Ophthalmol. 2026 Feb; 264(2):407-416.
-
Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment. Eye (Lond). 2025 Dec; 39(17):3045-3057.
-
Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review. Surv Ophthalmol. 2026 Mar-Apr; 71(2):289-308.
-
Predicting treatment response in retinal vein occlusions using baseline optical coherence tomography biomarkers: A systematic review. Surv Ophthalmol. 2026 Jan-Feb; 71(1):100-118.
-
Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis. Ophthalmology. 2026 Jan; 133(1):75-90.
-
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease. Am J Physiol Heart Circ Physiol. 2025 Aug 01; 329(2):H490-H504.
-
Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis. Ophthalmology. 2025 Nov; 132(11):1241-1252.
-
Short-term effects of tetracycline use in patients with diabetic retinopathy. Can J Ophthalmol. 2025 Dec; 60(6):e858-e868.